You are here


francesca wuttke startup generation nen

Francesca Domenech Wuttke

CEO and Founder of Nen

PhD in Pharmacology from the Weill Cornell Graduate School of Medical Sciences (New York) and a degree in Biology and Society from Cornell University (New York). She has extensive experience in drug development and healthcare, both in the United States and Europe. She has worked at several organizations, accelerating and incubating startups, heading up European investments and leading mergers and acquisitions of medical devices and pharmaceuticals.


Gisela Lorente Marina

Chief Scientific Officer (CSO) 

She has a PhD in biomedicine from the University of Barcelona and over 8 years of experience in scientific research in the field of cancer. She has worked as head of innovation and technology transfer at IDIBELL, where she was part of setting up Aptadel Therapeutics. 


Joan Bertran

Founder and CEO

Joan Bertran is a textile engineer, specializing in technical fabrics. In this field, he has worked in the aeronautics, automobile, renewable energy and, most recently, biomedical sectors. He has been director of operations and a member of the executive board at international textile companies. He has a master in Operations Management and an MBA. When a friend’s daughter died of cancer, he was inspired to become an entrepreneur in biotechnology. 

roger gomis

The study led by the IRB Barcelona may open up new pathways in oncology therapy

BDebate Epigenetics and Cancer

On 29 and 30 October, international experts met at CosmoCaixa, called together by B·Debate, an initiative of Biocat and the "la Caixa" Foundation, to debate the latest advances in the epigenetics of cancer for the third consecutive year

Data publicació: 


Dr. Manel Esteller, ICREA research professor, head of the Cancer Epigenetics and Biology Program at the Biomedical Research Institute of Bellvitge (IDIBELL) and professor of genetics at the University of Barcelona

Our genome isn’t the only thing to blame for our behavior towards and susceptibility to cancer.